Lersivirine – a new drug for HIV infection therapy

Bibliography

• UNAIDS. UNAIDS Report On The Global AIDS Epidemic. 2012. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf [Cited 12 March 2013]
   Google Scholar
• Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65(3):445-8
   PubMed Web of Science ®Google Scholar
• Turpin JA. The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets. Expert Rev Anti Infect Ther 2003;1(1):97-128
   PubMedGoogle Scholar
• Mori J, Thornberry A, Perros M, et al. In vitro passage of HIV-1 in the presence of the next-generation NNRTI, lersivirine (UK-453,061): phenotypic and genotypic observations, poster 63. European HIV Drug Resistance Workshop; 2009
   Google Scholar
• Fätkenheuer G, Staszewski S, Plettenburg A, et al. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS 2009;23(16):2115-22
   PubMed Web of Science ®Google Scholar
• Corbau R, Mori J, Phillips C, et al. Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2010;54(10):4451-63
   PubMed Web of Science ®Google Scholar
• Phillips C, Irving S, Ringrose H, et al. HIV-1 reverse transcriptase structure-based drug design: crytals to clinic. Acta Crystallograph 2007;63:18
   Google Scholar
• Pelemans H, Esnouf R, De Clercq E, et al. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. Mol Pharmacol 2000;57(5):954-60
   PubMed Web of Science ®Google Scholar
• Mori J, Corbau R, Lewis D. In vitro characterization of UK-453,061, a non-nucleoside reverse transcriptase inhibitor. 15th Conference on Retroviruses and Opportunistic Infections; 3 – 6 February 2008; Boston, MA, USA
   Google Scholar
• Vourvahis M, Banerjee S, LaBadie R, et al. Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine. Antimicrob Agents Chemother 2010;54(5):2209-11
   PubMed Web of Science ®Google Scholar
• Allan G, Davis J, Dickins M, et al. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. Xenobiotica 2008;38(6):620-40
   PubMed Web of Science ®Google Scholar
• Davis J, Jenkins T, Asken E, et al. Pharmacokinetics of single and multiple oral doses of UK-453,016, a novel NNRTi, in healthy male subjects. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22 – 25 July 2007; Sydney, Australia
   Google Scholar
• Weatherley B, McFadyen L, Langdon G. Population pharmacokinetics of lersivirine using Phase I/IIa pharmacokinetic data after suspension and tablet administration. Poster P07. 12th International Workshop on the Clinical Pharmacology of HIV Therapy; 13 – 15 April 2011; Miami, FL, USA
   Google Scholar
• Vourvahis M, Gleave M, Nedderman AN, et al. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dic arbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos 2010;38(5):789-800
   PubMed Web of Science ®Google Scholar
• Langdon G, Davis J, Layton G, et al. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects. Br J Clin Pharmacol 2012;73(5):768-75
   PubMed Web of Science ®Google Scholar
• Walker DK, Davis J, Houle C, et al. Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations. Xenobiotica 2009;39(7):534-43
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Langdon G, Layton G, et al. The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects. J Acquir Immune Defic Syndr 2012;60(1):24-32
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Gleave M, Nedderman A, et al. Mass balance of Lersivirine (UK-453,061), a next-generation NNRTI, following administration of [14C] lersivirine to healthy subjects, poster P61. 10th Int Workshop Clin Pharmacol HIV Ther; 15 – 17 April 2009; Amsterdam, Netherlands
   Google Scholar
• Vourvahis M, Langdon G, Labadie RR, et al. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects. Antimicrob Agents Chemother 2012;56(2):887-92
   PubMed Web of Science ®Google Scholar
• Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46(2):111-16
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Davis J, Langdon G, et al. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. Antivir Ther 2013
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Davis J, Wang R, et al. Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects. Antimicrob Agents Chemother 2012;56(8):4303-9
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Wang R, Gruener DM, et al. Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers. Drug Alcohol Depend 2012;126(1-2):183-8
   PubMed Web of Science ®Google Scholar
• Crauwels HM, Kakuda TN. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2010;49(1):67-8. author reply 68-9
   PubMed Web of Science ®Google Scholar
• Davis J, Langdon G, Layton G, et al. The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects. Eur J Clin Pharmacol 2012;68(11):1567-72
   PubMed Web of Science ®Google Scholar
• Vernazza P, Wang C, Pozniak A, et al. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr 2013;62(2):171-9
   PubMed Web of Science ®Google Scholar
• M. M. Update Status of Lersivirine Development Program. 2013. Available from: http://www.viivhealthcare.com/∼/media/Files/G/GlaxoSmithKline-Plc/pdfs/February 2013 Lersivirine Update.pdf [Cited 11 July 2013]
   Google Scholar
• Kar P, Knecht V. Energetics of mutation-induced changes in potency of lersivirine against HIV-1 reverse transcriptase. J Phys Chem B 2012;116(22):6269-78
   PubMed Web of Science ®Google Scholar
• Vernazza P, Wang C, Pozniak A, et al. Efficacy and safety of lersivirine vs efavirenz in antiretroviral treatment-naive HIV-1-infected patients: Week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase 2b trial (Study A5271015). 6th IAS conference on HIV pathogenesis, treatment and prevention; 17 – 20 July 2011; Rome, Italy
   Google Scholar
• Jones LH, Allan G, Corbau R, et al. Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers. Chem Biol Drug Des 2011;77(5):393-7
   PubMed Web of Science ®Google Scholar
• Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005;79(20):12773-82
   PubMed Web of Science ®Google Scholar
• Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54(2):718-27
   PubMed Web of Science ®Google Scholar
• Davis J, Hackman F, Ndongo MN, et al. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clin Ther 2010;32(11):1889-95
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Wang R, Ndongo MN, et al. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects. Antimicrob Agents Chemother 2012;56(5):2408-13
   PubMed Web of Science ®Google Scholar
• Davis J. Safety, toleration and pharmacokinetics of single and multiple oral doses of UK-453,061, a novel NNRTI, in healthy male subjects. 4th Int AIDS Soc Conf HIV Pathog, Treatment, Prev; Sydney, Australia; 2007
   Google Scholar
• Campion SN, Bowman CJ, Cappon GD, et al. Developmental toxicity of lersivirine in rabbits when administered throughout organogenesis and when limited to sensitive windows of axial skeletal development. Birth Defects Res B Dev Reprod Toxicol 2012;95(3):250-61
   PubMed Web of Science ®Google Scholar
• Cappon GD, Bowman CJ, Campion SN, et al. Developmental toxicity study of lersivirine in mice. Birth Defects Res B Dev Reprod Toxicol 2012;95(3):225-30
   PubMed Web of Science ®Google Scholar
• Tibotec. Important Drug Warning. 2009. Available from: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM180594.pdf [Cited 24 August 2013]
   Google Scholar